![](https://monteverdelaw.com/wp-content/uploads/case-logo/acceleron-pharma-inc.jpg)
Acceleron Pharma Inc. (XLRN) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own.
Acceleron Pharma Inc. (XLRN) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own.